Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Viemed reports record Q2 revenue, raises 2026 guidance, and initiates buyback

Aug 3, 2026, 5:04 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Material beat on revenue, notable user growth, and raised guidance create positive sentiment; buyback reduces share count; modest debt and strong cash flow support a favorable re-rating, though valuation and execution risk remain.

AI summary

What happened, with direct paths to the underlying reporting

Viemed posted a Q2 revenue record of $78.1M and raised 2026 net revenue guidance to $314-320M. The company also reported $2.8M in net income and $13.7M Adjusted EBITDA, while repurchasing 530,802 shares at an average $9.65. Strong ventilator and PAP growth supports the outlook, suggesting near-term upside for VMD.

Q2 2026 revenue record: $78.1M; up 23.9% YoY.
Net income $2.8M; EPS $0.07; Adj EBITDA $13.7M, -4% YoY.
Operating cash flow $15.9M; trailing 12 months $60.8M; FCF $8.6M.
Share buyback: 530,802 shares, $5.1M, avg $9.65.
Updated 2026 guidance: revenue $314-320M; EBITDA $64-68M; capex 8.5-10%.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.